Natera Prices Public Offering of 11.43 Million Shares at $35.00 per Share

Trending News ☀️

Natera ($NASDAQ:NTRA), Inc. is a biotechnology company that develops and commercializes products based on its proprietary genetic testing technology for reproductive health, oncology, and organ transplantation in the United States and internationally. Natera has priced its underwritten public offering of 11.43 million shares of its common stock at a price to the public of $35.00 per share.

Stock Price

Natera‘s stock opened at $36.7 on Wednesday and closed at $36.7, a 7.5% increase from its last closing price of $34.2. This public offering comes as Natera looks to expand its business and continue providing accurate and reliable testing for pregnant women and those considering starting a family. With the additional funds, Natera will be able to further its mission of helping families grow.

VI Analysis

NATERA is a strong company in terms of assets and growth, but is weak in terms of dividend and profitability. It is classified as a ‘cheetah’, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. This makes it less likely to pay off debt and fund future operations. However, NATERA’s strong fundamentals reflect its long-term potential, making it an attractive investment for growth-oriented investors.

VI Peers

The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.

– Genetic Technologies Ltd ($ASX:GTG)

Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.

– Dr Lalchandani Labs Ltd ($BSE:541299)

Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.

– NeoGenomics Inc ($NASDAQ:NEO)

NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.

Summary

If you’re considering investing in NATERA, you may want to keep an eye on the company’s stock price. In general, NATERA has been doing well lately, with the stock price moving up the past few days. However, as with any investment, there’s always a risk that the stock price could drop in the future. So, it’s important to do your research and make sure you’re comfortable with the risks before investing.